Amir Azarbal, MD
Cardiovascular Disease · Jacksonville, FLNPI 1679830632
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.1%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Medtronic at 40.3% of the total. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $83.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Abiomed$4K
- Abbott$3K
- Edwards Lifesciences$2K
- Inari Medical, Inc.$2K
- Boston Scientific$970
- plus $5K from 29 others
Across 7 payments — averaging $2658.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$19K
What the payments were for
- Grants$10,32237%
- Travel & lodging$3,62713%
- Food & beverage$14,03550%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 27 | $11,274 |
| Abiomed | 29 | $3,522 |
| Abbott | 41 | $3,468 |
| Edwards Lifesciences | 18 | $2,339 |
| Inari Medical, Inc. | 21 | $1,558 |
| Boston Scientific | 12 | $970 |
| Biosense Webster, Inc. | 15 | $957 |
| Stryker | 72 | $613 |
| Cvrx, Inc. | 8 | $389 |
| Philips North America LLC | 6 | $322 |
| Impulse Dynamics (USA) Inc. | 8 | $322 |
| AstraZeneca | 4 | $265 |
| Johnson & Johnson | 18 | $263 |
| Novartis | 6 | $188 |
| Baxter Healthcare | 9 | $177 |
| Bard Peripheral Vascular, Inc. | 4 | $152 |
| Contego Medical, Inc | 1 | $149 |
| ZOLL Circulation Inc | 1 | $132 |
| Lexicon Pharmaceuticals, Inc. | 1 | $120 |
| Pfizer | 6 | $116 |
| Alnylam Pharmaceuticals Inc. | 1 | $111 |
| Boehringer Ingelheim | 5 | $100 |
| Cardiovascular Systems Inc. | 2 | $87 |
| Teleflex LLC | 1 | $78 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Cardiva Medical, Inc. | 3 | $55 |
| Amgen | 3 | $49 |
| Merck | 2 | $32 |
| Imperative Care, Inc | 1 | $26 |
| Shockwave Medical, Inc | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $21 |
| Coloplast | 1 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $20 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$10,322
- Impella$2,290
- FLOWTRIEVER CATHETER, S$1,408
- CT THROMBECTOMY SYSTEM KIT$1,408
- MitraClip$1,128
- NAVITOR$1,063
- Carto 3$723
- SAPIEN 3 Ultra RESILIA$537
- WATCHMAN FLX$444
- Edwards SAPIEN 3 Transcatheter Heart Valve$416
- OPTIMIZER$360
- Barostim Neo System$294
- FARXIGA$241
- CARDIOMEMS$236
- AMPLATZER AMULET$158
- ONYX FRONTIER$157
- VenaSeal$141
- LIMFLOW SYSTEM$140
- TherOx DS2 Console$132
- Catheter$132
How this compares
$28,002 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 24 | $20,822 |
| EliquisApixaban | 14 | $9,978 |
| ClopidogrelClopidogrel Bisulfate | 24 | $262 |
| Bumetanide | 15 | $254 |
| Atorvastatin Calcium | 20 | $176 |
| Metoprolol Succinate | 12 | $164 |
| Metoprolol Tartrate | 14 | $160 |
| Furosemide | 21 | $95 |
| Pantoprazole Sodium | 13 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $263 | $20,82224 claims |
| PfizerEliquis | $116 | $9,97814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Jacksonville
- Alan MillerJacksonville$547K
- Samer GarasJacksonville$258K
- Jose Nativi-NicolauJacksonville$125K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.